Main Facts: A Paradigm Shift for Geriatric Obesity Care
A comprehensive new analysis of the STEP clinical trial program has provided significant clarity on the role of semaglutide—the active pharmaceutical ingredient in the blockbuster medications Wegovy and Ozempic—among the geriatric population. For years, clinicians have approached the use of glucagon-like peptide-1 (GLP-1) receptor agonists in patients aged 65 and older with a degree of caution. Concerns regarding frailty, muscle mass loss, and the potential for complex drug-drug interactions in patients with multi-morbidity have historically limited the widespread prescription of these therapies in older demographics.
However, the latest findings, led by Professor Luca Busetto of the University of Padova, suggest that semaglutide 2.4 mg is not only effective at facilitating significant weight loss in this age group but does so with a safety profile consistent with younger cohorts. The study, which synthesized data from six distinct STEP trials (1, 3, 4, 5, 8, and 9), confirms that adults over 65 with obesity can achieve weight reductions and cardiometabolic improvements that mirror those seen in the general adult population, potentially offering a new pathway to mitigate age-related chronic disease and disability.
Chronology of the STEP Analysis
To arrive at these conclusions, researchers conducted a retrospective, pooled analysis of data specifically isolating participants aged 65 and older who did not have a diagnosis of diabetes. By excluding patients with diabetes, the researchers ensured that the weight-loss efficacy was not confounded by the metabolic complexities associated with glucose-lowering therapy, allowing for a "cleaner" look at how the drug affects adiposity and cardiovascular risk factors.
The research process spanned the following stages:
- Cohort Selection: The researchers identified 358 participants aged 65 or older from a total pool of 4,523 trial participants. Of these, 248 were randomized to receive a once-weekly subcutaneous injection of 2.4 mg semaglutide, while 110 received a placebo.
- Baseline Benchmarking: At the study’s inception, the average age of participants was 69. The cohort presented with an average body weight of 99.0 kg and a mean Body Mass Index (BMI) of 36.6 kg/m². Notably, 72% of the participants were women.
- The 68-Week Intervention: Participants underwent a 68-week intervention period. During this time, they were monitored for changes in body weight, waist circumference, waist-to-height ratio (WHtR), and various cardiometabolic markers, including blood pressure, lipid profiles, and hs-CRP levels.
- Data Synthesis: The findings were consolidated to compare the semaglutide group against the placebo group, with all participants receiving standardized lifestyle interventions to ensure baseline consistency.
Supporting Data: Efficacy and Health Metrics
The clinical outcomes reported at the 68-week mark were striking, particularly given the historical difficulty in achieving meaningful weight loss in older adults due to slower metabolic rates and decreased physical activity levels.
Weight Loss Milestones
The semaglutide group experienced an average body weight reduction of 15.4%, a stark contrast to the 5.1% reduction observed in the placebo group. Even more compelling were the categorical improvements:
- 10% Weight Loss: 66.5% of semaglutide users achieved this threshold, compared to 15.5% of placebo users.
- 15% Weight Loss: 46.8% of the semaglutide group reached this milestone, versus 6.4% in the placebo group.
- 20% Weight Loss: Nearly one-third (28.6%) of the semaglutide cohort achieved a 20% reduction in total body weight, while only 2.7% of the placebo group managed the same.
Waist Circumference and BMI Transformation
Beyond the scale, the physical measurements signaled a significant reduction in visceral fat, which is the primary driver of cardiovascular risk in older adults. The semaglutide group saw an average reduction in waist circumference of 14.3 cm, more than double the 6.0 cm reduction seen in the placebo arm.
Furthermore, the shift in BMI categories was pronounced. By the conclusion of the study, 27% of those on semaglutide achieved a "healthy" BMI of less than 27 kg/m², compared to just 5.5% in the placebo group. This transition reflects a fundamental improvement in the participants’ physical status, moving them out of high-risk obesity classifications.
Cardiometabolic Benefits
The study recorded systemic improvements in health markers that are critical for longevity. Participants on semaglutide showed significant decreases in systolic and diastolic blood pressure, improved cholesterol profiles, and lower levels of glycated hemoglobin (HbA1c). These markers are essential indicators of reduced risk for stroke, myocardial infarction, and long-term metabolic syndrome.
Official Responses and Safety Considerations
The safety profile of semaglutide in older populations is perhaps the most scrutinized aspect of the research. The study reported that overall rates of adverse events (AEs) were comparable, with 89.1% of the semaglutide group and 84.5% of the placebo group experiencing some form of event.
However, the researchers noted a higher incidence of "serious" adverse events in the semaglutide group (19.0%) compared to the placebo group (12.7%). While this requires clinical oversight, the researchers pointed out that common side effects, such as gastrointestinal distress (constipation) and dizziness, were consistent with the known mechanism of action for GLP-1 receptor agonists. Crucially, the incidence of severe complications, such as fractures and hypoglycemia, remained low and did not differ significantly between the two groups, providing reassurance that the medication does not induce the "frailty" often feared by geriatricians.
Professor Busetto and his colleagues, which included researchers from Novo Nordisk (the study’s sponsor), maintained that the benefit-risk ratio remains favorable. The data suggests that for most older adults, the improvement in cardiometabolic health far outweighs the risk of common, manageable gastrointestinal side effects.
Implications: A New Standard for Aging Populations
The implications of these findings are profound for global public health. In many high-income nations, the highest prevalence of obesity is now observed in adults aged 65 and older. As the global population ages, this demographic is increasingly prone to obesity-related disabilities—such as osteoarthritis, sleep apnea, and cardiovascular strain—which diminish quality of life and place an immense burden on healthcare systems.
Addressing the Quality-of-Life Gap
The "health span" (the number of years lived in good health) is the primary concern for the aging population. By demonstrating that semaglutide is effective in this age bracket, the medical community now has a validated tool to help older patients regain mobility and reduce their reliance on polypharmacy for blood pressure and cholesterol management.
Moving Forward
The researchers emphasize that while these results are encouraging, they should be integrated into a comprehensive care plan. The study highlights that semaglutide is most effective when paired with lifestyle interventions, such as those used in the STEP 3 protocol, which included intensive behavioral therapy.
As the medical community digests these findings, the focus will likely shift toward personalized treatment protocols. Clinicians are encouraged to screen for potential contraindications, such as specific pre-existing gastrointestinal conditions, but the "age-old" barrier to using weight-loss medication appears to have been effectively dismantled. With further real-world evidence and long-term longitudinal studies, semaglutide may soon become a cornerstone of geriatric medicine, helping millions of older adults move from a state of metabolic vulnerability to one of increased vitality and health.
